A | CMET+ | CMET– | p†|
---|---|---|---|
Overall | Â | Â | Â |
 All embolic events | 21% (24) | 8% (9) | 0.006 |
 Pulmonary embolism* | 13% (14) | 5% (6) | 0.08 |
 CVA†| 8% (9) | 4% (4) | 0.23 |
 Peripheral embolism | 5% (5) | 0% (–) | – |
Right-sided involvement (n = 65) |  |  |  |
 All embolic events | 31% (20) | 8% (5) | 0.001 |
Pulmonary embolism | 20% (13) | 6% (4) | 0.02 |
 CVA | 9% (6) | 3% (2) | 0.22 |
 Peripheral embolism | 8% (5) | 0% (–) | – |
Left-sided involvement (n = 56) |  |  |  |
 All embolism | 13% (7) | 7% (4) | 0.55 |
 Pulmonary embolism | 4% (2) | 5% (3) | 1.00 |
 CVA | 7% (4) | 2% (1) | 0.38 |
 Peripheral embolism | 2% (1) | 0% (–) | – |
Intra-cavitary metastasis | Â | Â | Â |
 Right-sided Involvement (n = 45) |  |  |  |
  All embolic events | 36% (16) | 9% (4) | 0.002 |
  Pulmonary embolism | 27% (12) | 7% (3) | 0.01 |
  CVA | 11% (5) | 4% (2) | 0.38 |
  Peripheral embolism | 7% (3) | 0% (-) | - |
 Left-sided Involvement (n = 31) |  |  |  |
  All embolic events | 29% (9) | 10% (3) | 0.15 |
  Pulmonary embolism | 16% (5) | 7% (2) | 0.45 |
  CVA | 13% (4) | 3% (1) | 0.38 |
  Peripheral embolism | 3% (1) | 0% (-) | - |
B | Heterogeneous enhancement CMET+ (n = 59) | Diffuse enhancement CMET+ (n = 53) | P |
---|---|---|---|
All embolic events | 24% (14) | 19% (10) | 0.53 |
Pulmonary embolism | 15% (9) | 9% (5) | 0.35 |
CVA | 10% (6) | 6% (3) | 0.50 |
Peripheral embolism | 2% (1) | 8% (4) | 0.19 |